» Articles » PMID: 35132204

AAV2-VEGF-B Gene Therapy Failed to Induce Angiogenesis in Ischemic Porcine Myocardium Due to Inflammatory Responses

Abstract

Therapeutic angiogenesis induced by gene therapy is a promising approach to treat patients suffering from severe coronary artery disease. In small experimental animals, adeno-associated viruses (AAVs) have shown good transduction efficacy and long-term transgene expression in heart muscle and other tissues. However, it has been difficult to achieve cardiac-specific angiogenic effects with AAV vectors. We tested the hypothesis whether AAV2 gene transfer (1 × 10 vg) of vascular endothelial growth factor B (VEGF-B186) together with immunosuppressive corticosteroid treatment can induce long-term cardiac-specific therapeutic effects in the porcine ischemic heart. Gene transfers were delivered percutaneously using direct intramyocardial injections, improving targeting and avoiding direct contact with blood, thus reducing the likelihood of immediate immune reactions. After 1- and 6-month time points, the capillary area was analyzed, myocardial perfusion reserve (MPR) was measured with radiowater positron emission tomography ([O]HO-PET), and fluorodeoxyglucose ([F]FDG) uptake was used to evaluate myocardial viability. Clinical chemistry and immune responses were analyzed using standard methods. After 1- and 6-month follow-up, AAV2-VEGF-B186 gene transfer failed to induce angiogenesis and improve myocardial perfusion and viability. Here, we show that inflammatory responses attenuated the therapeutic effect of AAV2 gene transfer by significantly reducing successful transduction and long-term gene expression despite the efforts to reduce the likelihood of immune reactions and the use of targeted local gene transfer methods.

Citing Articles

Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy.

Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E Viruses. 2025; 17(2).

PMID: 40006994 PMC: 11861813. DOI: 10.3390/v17020239.


Strategies to improve safety profile of AAV vectors.

Suoranta T, Laham-Karam N, Yla-Herttuala S Front Mol Med. 2024; 2:1054069.

PMID: 39086961 PMC: 11285686. DOI: 10.3389/fmmed.2022.1054069.


Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic perfusion.

Schmalkuche K, Rother T, Burgmann J, Voss H, Hoffler K, Dogan G Front Immunol. 2024; 15:1404668.

PMID: 38903492 PMC: 11188324. DOI: 10.3389/fimmu.2024.1404668.


Machine-learning-guided Directed Evolution for AAV Capsid Engineering.

Fu X, Suo H, Zhang J, Chen D Curr Pharm Des. 2024; 30(11):811-824.

PMID: 38445704 DOI: 10.2174/0113816128286593240226060318.


Salvianolic acid B promotes angiogenesis and inhibits cardiomyocyte apoptosis by regulating autophagy in myocardial ischemia.

Chen Q, Xu Q, Zhu H, Wang J, Sun N, Bian H Chin Med. 2023; 18(1):155.

PMID: 38017536 PMC: 10685573. DOI: 10.1186/s13020-023-00859-w.


References
1.
Kawase Y, Ly H, Prunier F, Lebeche D, Shi Y, Jin H . Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008; 51(11):1112-9. DOI: 10.1016/j.jacc.2007.12.014. View

2.
Kivela R, Bry M, Robciuc M, Rasanen M, Taavitsainen M, Silvola J . VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med. 2014; 6(3):307-21. PMC: 3958306. DOI: 10.1002/emmm.201303147. View

3.
Yla-Herttuala S, Bridges C, Katz M, Korpisalo P . Angiogenic gene therapy in cardiovascular diseases: dream or vision?. Eur Heart J. 2017; 38(18):1365-1371. PMC: 5837788. DOI: 10.1093/eurheartj/ehw547. View

4.
Mingozzi F, High K . Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013; 122(1):23-36. PMC: 3701904. DOI: 10.1182/blood-2013-01-306647. View

5.
Rakoczy E, Lai C, Magno A, Wikstrom M, French M, Pierce C . Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015; 386(10011):2395-403. DOI: 10.1016/S0140-6736(15)00345-1. View